Fianlimab - Regeneron Pharmaceuticals
Alternative Names: Anti-LAG-3 antibody; REGN-3767Latest Information Update: 20 Jun 2024
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Malignant melanoma
- Phase II/III Non-small cell lung cancer
- Phase II Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 07 Jun 2024 Phase-II clinical trials in Non-small cell lung cancer (Newly diagnosed, Early-stage disease, Combination therapy) in USA (IV) (EudraCT2023-505172-29-00) (NCT06161441)
- 31 May 2024 Updated efficacy and adverse events data from a phase I trial in Haematological malignancies presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 May 2024 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Late-stage disease) in Australia (Parenteral)